Skip to Main Content

Author Details

Yang Shao
Nanjing Geneseeq Technology Inc.
2012
172
31
PMIDPaper TitleJournal TitlePublished Year
37885353Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing.Mol Oncol2024
36346614Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.Am J Respir Crit Care Med2023
37588206Clinical and genomic analysis of baseline and acquired <i>MET</i> fusions with an intact kinase domain in lung cancer patients.Genes Dis2023
37248810Molecular risk factors for locoregional recurrence in resected non-small cell lung cancer.Cancer Med2023
37377889Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics.Cancer Res Commun2023
37339686Genomic and Transcriptomic Remodeling by Neoadjuvant Chemoradiotherapy (nCRT) and the Indicative Role of Acquired INDEL Percentage for nCRT Efficacy in Esophageal Squamous Cell Carcinoma.Int J Radiat Oncol Biol Phys2023
37072406Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy.Oncogenesis2023
36751810Poly(ADP-ribose) polymerase family member 14 promotes functional recovery after spinal cord injury through regulating microglia M1/M2 polarization via STAT1/6 pathway.Neural Regen Res2023
36694231The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses.Biomark Res2023
36308331Utility of Circulating Free DNA Fragmentomics in the Prediction of Pathological Response after Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.Clin Chem2023
35995891Tumor mutational burden and efficacy of chemotherapy in lung cancer.Clin Transl Oncol2023
36325957Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.Cancer Med2023
33115932Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies <i>KRAS</i> mutation as a biomarker of poor prognosis.J Med Genet2022
35586877Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.Cancer Med2022
35444698Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer.J Oncol2022
35506567NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.Cancer Med2022
35578198Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.BMC Cancer2022
35498538Somatic Alteration Characteristics of Early-Onset Gastric Cancer.J Oncol2022
35690859Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection.Mol Cancer2022
35452192Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial.Clin Transl Med2022
35780566Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.EBioMedicine2022
35451500Tumor-infiltrating lymphocytes-based subtypes and genomic characteristics of EBV-associated lymphoepithelioma-like carcinoma.J Pathol2022
35590322The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients.Mol Cancer2022
36183093Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer.J Hematol Oncol2022
35912186Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer.Front Oncol2022
35870258Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.Lung Cancer2022
35901658Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.EBioMedicine2022
36202008Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.Drug Resist Updat2022
36059009RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.J Transl Med2022
35950410Investigating and modeling the differential DNA methylation for early lung adenocarcinoma diagnosis.Biomark Med2022
36257481Associations of genome-wide cell-free DNA fragmentation profiles with blood biochemical and hematological parameters in healthy individuals.Genomics2022
35046666Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy.Onco Targets Ther2022
34954829Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.Hepatology2022
34922300Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.ESMO Open2022
35014626Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial.JCI Insight2022
35123209Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.ESMO Open2022
35150094Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.Thorac Cancer2022
35038823Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation.Cancer Res Treat2022
35180847The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.BMC Cancer2022
35303266Cytokine-driven positive feedback loop organizes fibroblast transformation and facilitates gastric cancer progression.Clin Transl Oncol2022
35076939Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.Cancer2022
34862662Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.APMIS2022
33231826Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer.Clin Exp Metastasis2021
33790576Identification of Novel Alectinib-Resistant <i>ALK</i> Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling.Onco Targets Ther2021
33737344Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.J Immunother Cancer2021
33710812Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer.Cancer Biol Med2021
33710807Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.Cancer Biol Med2021
33505917Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.Front Oncol2021
33811322The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.Int J Cancer2021
33747936Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.Front Oncol2021
  • 1 - 50 of 172

Recommended Authors

Majd Al Assaad
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2018
Number of shared co-authors 0
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Career Start Year 2016
Number of shared co-authors 1
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Career Start Year 2016
Number of shared co-authors 0
Zhixin Qiu
UPMC Hillman Cancer Center
Career Start Year 2012
Number of shared co-authors 1
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 2
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 3
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2007
Number of shared co-authors 1
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 2
Sadakatsu Ikeda
Tokyo Medical and Dental University Hospital
Career Start Year 2006
Number of shared co-authors 0
Li Liu
Central South University
Career Start Year 2006
Number of shared co-authors 0
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 3
Iacopo Petrini
University of Pisa
Career Start Year 2006
Number of shared co-authors 0
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 1
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 2
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 0
Jeeyun Lee
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2003
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 3
Debyani Chakravarty
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 0
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 1
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 1
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 2
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 1
Woong-Yang Park
Samsung Genome Institute, Samsung Medical Center
Career Start Year 1995
Number of shared co-authors 1
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 3
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 2
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 1

Collaborators

Xue Wu
Nanjing Geneseeq Technology Inc.
Co-authored papers 97
Rama Khokha
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 7
Paul D Waterhouse
Princess Margaret Cancer Centre/University Health Network
Co-authored papers 4
Hui Fang
Beihua University
Co-authored papers 4
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers 2
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 2
Yu-Jia Shiah
Ontario Institute for Cancer Research
Co-authored papers 1
H??l??ne Hovington
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Co-authored papers 1
Youri Hoogstrate
Erasmus MC Cancer Institute
Co-authored papers 1
Anna Lapuk
Contextual Genomics Inc.
Co-authored papers 1
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 1
Jeffrey L Wrana
Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital
Co-authored papers 1
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 1
Pirashaanthy Tharmapalan
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 1
Fan Zhang
Huaihe Hospital of Henan University
Co-authored papers 1
Junjie T Hua
School of Public Health, Sun Yat-sen University
Co-authored papers 1
Vinayak Bhandari
University of Toronto
Co-authored papers 1
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Li Yao
Co-authored papers 1
Fouad Yousif
Ontario Institute for Cancer Research
Co-authored papers 1
Lawrence E Heisler
Ontario Institute for Cancer Research
Co-authored papers 1
Jixi Li
People's Hospital of Henan University, Henan Provincial People's Hospital
Co-authored papers 1
Robert G Bristow
University of Toronto
Co-authored papers 1
Ming Shi
Co-authored papers 1
Natalie S Fox
University of California los angeles
Co-authored papers 1
Bernard T??tu
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Co-authored papers 1
Miranda Wang
Princess Margaret Cancer Center/University Health Network
Co-authored papers 1
Val??rie Picard
Centre de recherche du CHU de Quebec-Universite Laval
Co-authored papers 1
Yuzhe Zhang
China University of Mining and Technology
Co-authored papers 1
Yves Fradet
CHU de Quebec-Universite Laval
Co-authored papers 1
Release 1.2